Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Hookipa Pharma Inc

HOOK
Current price
3.7 USD -0.04 USD (-1.07%)
Last closed 3.76 USD
ISIN US43906K1007
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 37 205 088 USD
Yield for 12 month -20.77 %
1Y
3Y
5Y
10Y
15Y
HOOK
21.11.2021 - 28.11.2021

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York. Address: 350 Fifth Avenue, New York, NY, United States, 10118

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

44.8 USD

P/E ratio

Dividend Yield

Current Year

+20 129 000 USD

Last Year

+14 249 000 USD

Current Quarter

+1 290 000 USD

Last Quarter

+36 599 000 USD

Current Year

+16 577 000 USD

Last Year

+14 249 000 USD

Current Quarter

+576 000 USD

Last Quarter

+35 959 000 USD

Key Figures HOOK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -47 709 000 USD
Operating Margin TTM -1736.74 %
PE Ratio
Return On Assets TTM -20.1 %
PEG Ratio
Return On Equity TTM -48.99 %
Wall Street Target Price 44.8 USD
Revenue TTM 52 163 000 USD
Book Value 7.14 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -51.8 %
Dividend Yield
Gross Profit TTM -52 966 000 USD
Earnings per share -4.12 USD
Diluted Eps TTM -4.12 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -93.16 %

Dividend Analytics HOOK

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History HOOK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 10.07.2024
Dividend Date

Stock Valuation HOOK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.9077
Price Sales TTM 0.7132
Enterprise Value EBITDA 0.4569
Price Book MRQ 0.4323

Financials HOOK

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators HOOK

For 52 weeks

3.41 USD 11.3 USD
50 Day MA 4.25 USD
Shares Short Prior Month 35 190
200 Day MA 6.29 USD
Short Ratio 0.84
Shares Short 26 040
Short Percent 0.34 %